ArticleJournal of managed care & specialty pharmacy2025
Cost per outcome of nivolumab + relatlimab vs BRAF + MEK inhibitor combinations for first-line treatment of
Kirollos S Hanna et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.